On July 6, Alebund Pharmaceuticals-B (09637.HK) declined 8.32% in regular trading, trading at 28.22 HKD/share, with turnover of approximately 2 million HKD.

The decline represents a continuation of post-IPO volatility. The company listed on the Hong Kong Stock Exchange on June 29 at an offer price of 22.60 HKD, surging 103.54% on its debut to close at 46.00 HKD. The stock subsequently experienced a sharp correction, falling over 50% intraday on July 2 before rebounding approximately 18.75% on July 3. Notable institutional support emerged on listing day, with Singapore's GIC increasing its stake by 872,000 shares at 44.08 HKD each, and LAV Asset Management purchasing 450,000 shares at 45.06 HKD, totaling approximately 58.72 million HKD in combined investment.

Alebund Pharmaceuticals is a biopharmaceutical company focused on kidney disease therapies. Its core product AP301, an oral phosphate binder for hyperphosphatemia, has completed China Phase III registration trials and is expected to file for NDA approval in the near term.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)